Manipal Well being Enterprises – IPO Word

Firm Overview

Manipal Well being Enterprises Restricted is a pan-India multispecialty hospital operator, operating 49 hospitals with 13,037 licensed beds throughout 14 states and union territories as of March 31, 2026. Its community is concentrated in three key areas — Karnataka, Maharashtra and Goa, and choose states of jap India (West Bengal, Odisha, Jharkhand and Sikkim) — and spans the metros of Bengaluru, Kolkata and Pune alongside a large non-metro presence, with the mattress base break up 46.78% metro and 53.22% non-metro.

The Firm served 7.63 million sufferers throughout its community in Fiscal 2026 and had 11,064 docs and 24,240 workers as of March 31, 2026. Its medical companies are centered on tertiary and quaternary care throughout cardiac sciences, oncology, neurosciences, gastro sciences, orthopedics and renal sciences, which contributed 64.30% of gross inpatient income in Fiscal 2026, and 41 of its 49 hospitals had been NABH-accredited. Progress has come by means of a mixture of natural growth and strategic acquisitions — together with AMRI (2023), Medica Synergie (2024) and the Sahyadri Group (October 2025) — with the community increasing from 33 hospitals and 9,520 licensed beds as of March 31, 2024 to 49 hospitals and 13,037 licensed beds as of March 31, 2026.

Supply Abstract

The Firm is endeavor a book-built problem at a worth band of ₹560 to ₹590 per Fairness Share, comprising a Contemporary Situation of 13,55,93,220 shares, aggregating as much as ₹8,000.00 crore and an Supply for Sale of as much as 21,613,834 Fairness Shares of face worth of ₹2 every by the Promoting Shareholders aggregating as much as ₹1,275.22 crore.

Objects of the Supply

• Compensation or prepayment, in full or partly, of sure excellent borrowings and accrued curiosity thereon availed by the Firm’s Materials Subsidiary, Manipal Hospitals Non-public Restricted. (₹5,552.76 crore from the Internet Proceeds of the Contemporary Situation, representing roughly 47.47% of the Firm’s whole consolidated excellent borrowings as at Might 31, 2026)
• Acquisition of a minority stake within the Firm’s stepdown Subsidiary, Sahyadri Hospitals Non-public Restricted — ₹574.00 crore; and
• Normal company functions (not exceeding 25% of the gross proceeds of the Contemporary Situation).

Trade Snapshot

The Firm operates within the Indian healthcare supply market, which contains In-patient Division (“IPD”) and Out-patient Division (“OPD”) companies offered by each authorities and personal gamers, with IPD contributing the majority of {industry} income. In keeping with the CRISIL Report, the market was valued at roughly ₹7.0 trillion in Fiscal 2025 and is estimated to have reached ₹7.6–7.8 trillion in Fiscal 2026, with the IPD phase accounting for 71–72% of worth. The market is projected to develop at a CAGR of 10–12% between Fiscal 2025 and Fiscal 2030 to succeed in ₹11.2–12.2 trillion, with IPD rising sooner at 10.5–12.5% and OPD at 8–10%. The market stays extremely fragmented, with massive personal hospitals accounting for less than about 20% of the general market in Fiscal 2026, and the personal sector’s share of therapies by worth is predicted to rise from 64% in Fiscal 2020 to roughly 69% by Fiscal 2030. Cardiac sciences (17%) and oncology (12%) are the biggest single-specialty segments.

Key structural development drivers for the {industry} embody:

• Rising chronic-disease burden and ageing demographics: the share of India’s inhabitants aged 60 and above is projected to rise from 10.5% in CY2023 to 12.6% by CY2030, and the 40–59 cohort from 22.1% to 24.4%, whereas the incidence of non-communicable illnesses is predicted to maintain rising by means of Fiscal 2030 — lifting demand for tertiary, quaternary and geriatric care.
• Rising incomes, well being consciousness and insurance coverage protection: rising disposable incomes (the share of households within the ₹150,000–200,000 annual earnings bracket rose to 40% in Fiscal 2024), enhancing well being consciousness, and health-insurance penetration of 41% in Fiscal 2024 alongside a gradual decline in out-of-pocket expenditure as a share of present well being expenditure, are collectively widening affordability and entry to high quality care.
• Structural shift towards personal suppliers, aided by authorities initiatives: India’s mattress density of about 16 hospital beds per 10,000 individuals in Fiscal 2025 stays properly under the worldwide common of 33, underscoring the growth runway, whereas schemes similar to PMJAY and the Ayushman Bharat Digital Mission (ABDM), coupled with overburdened public infrastructure, are anticipated to channel an rising share of demand to personal gamers.

Funding Rationale

India’s largest hospital community by mattress capability with entrenched regional and metro management

Manipal ranks #1 amongst personal hospital chains by mattress capability and #2 by variety of hospitals, and reported the second-highest income from operations in Fiscal 2026. It has the widest hospital footprint of any personal chain, holds the main place in every of its three key areas, and is the one personal chain to guide by mattress capability throughout three metros — benefits constructed on scale, density and referral attain which are capital-intensive and troublesome to duplicate.

Diversified throughout high-acuity specialties, geographies and payors

Income is unfold throughout a broad specialty base whereas anchored in advanced, high-value care: CONGO-R specialties (cardiac sciences, oncology, neurosciences, gastro sciences, orthopedics and renal sciences) contributed 64.30% of gross inpatient income in Fiscal 2026, with no single specialty dominating. The community is balanced throughout metros (46.78% of licensed beds) and non-metros (53.22%), the latter providing higher-growth, under-penetrated catchments. The payor combine can also be diversified — TPA/insurance coverage 49.68%, money 30.33%, authorities 13.80% and others 6.19% of gross inpatient income in Fiscal 2026 — which, alongside disciplined working-capital administration, supported a unfavorable working-capital cycle of 13 days in Fiscal 2026. In observe, this unfold insulates income from any single specialty, metropolis or payor shock, whereas the CONGO-R skew retains the combo anchored to probably the most worthwhile, fastest-growing procedures.

Confirmed, repeatable acquisition-and-integration playbook driving sector-leading development

Between March 31, 2021 and March 31, 2026, Manipal was the main consolidator amongst personal hospital chains by beds added by means of acquisitions (5,548 beds), and it has a monitor file of upgrading acquired belongings by deepening high-acuity companies and instituting disciplined working practices. That is seen within the margin uplift achieved post-acquisition, illustrated under, and underpinned the corporate’s industry-leading income development over Fiscal 2024–Fiscal 2026.

Monetary Efficiency

Income from operations grew at a CAGR of 29.41% over Fiscal 2024–Fiscal 2026 to ₹10,335.75 crore, and EBITDA (excluding distinctive gadgets) at a CAGR of 25.45% to ₹2,795.94 crore. Revenue after tax, nevertheless, declined to ₹916.52 crore in Fiscal 2026 from ₹1,081.67 crore in Fiscal 2025: Fiscal 2025 had benefited from an unusually low tax cost (together with a ~₹130 crore deferred-tax credit score), whereas Fiscal 2026 absorbed a ~69% rise in finance prices (to ₹864.29 crore) and better depreciation from debt-funded acquisitions, an distinctive loss, and a normalised tax charge — compressing PAT margin to eight.87% and RoNW to 10.57%. The ₹5,552.76 crore of debt reimbursement deliberate from Contemporary Situation proceeds is predicted to materially decrease finance prices and help a restoration in returns.

Key Dangers

• Supply for Sale element and use of Contemporary Situation proceeds
  On the worth band, the Supply for Sale of as much as 21,613,834 Fairness Shares (~₹1,275 crore on the Cap, roughly 14% of the full Supply) represents a partial monetisation by promoter-group and investor promoting shareholders, and the Firm receives no proceeds from it. Of the ₹8,000 crore Contemporary Situation, about ₹6,127 crore (~77%) is earmarked for debt reimbursement and the acquisition of a minority stake in Sahyadri, so the first capital funding incremental development is proscribed relative to the headline problem dimension.
• Elevated leverage and finance prices
  Internet Debt (together with lease liabilities) to Adjusted EBITDA rose to three.74x in Fiscal 2026 from 2.00x in Fiscal 2025, and whole consolidated borrowings stood at ₹11,185.02 crore as at Might 31, 2026, reflecting debt-funded acquisitions (notably the Sahyadri Group). Finance prices jumped ~69% year-on-year to ₹864.29 crore in Fiscal 2026 which — along with larger depreciation and a normalised tax charge — pushed revenue after tax down and compressed RoNW to 10.57%. The deliberate ₹5,552.76 crore of debt reimbursement from Contemporary Situation proceeds ought to ease this, however till deployed, leverage and curiosity prices proceed to weigh on earnings.
• Acquisition-led development with integration and goodwill threat
  A big share of the growth from 33 hospitals and 9,520 beds (March 31, 2024) to 49 hospitals and 13,037 beds (March 31, 2026) has come by means of acquisitions, and goodwill on the stability sheet rose to ₹8,120.57 crore as at March 31, 2026. Realising the focused margin uplift and integration advantages at not too long ago acquired hospitals (as achieved traditionally with Columbia Asia) isn’t assured; delays, underperformance, or any impairment of goodwill might have an effect on returns.

Outlook

Manipal is positioned to develop alongside a structurally increasing Indian hospital market, underpinned by its #1 bed-capacity scale, entrenched regional and metro management, a high-acuity CONGO-R focus, and a confirmed acquisition-and-integration playbook, with post-issue deleveraging offering an additional earnings lever. Close to-term watch gadgets embody elevated leverage and finance prices, the margin and RoNW compression seen in Fiscal 2026 from acquisition-related prices, and execution and integration of latest acquisitions, notably the Sahyadri Group. The longer-term case rests on rising healthcare penetration, the continued shift towards personal suppliers, and the corporate’s skill to transform its scale and acquisition pipeline into higher-margin, higher-return development.

Valuation & View

In keeping with the RHP, the corporate’s listed friends are Apollo Hospitals Enterprise, Fortis Healthcare and Max Healthcare Institute. The peer group is buying and selling at a median P/E of 70.31x, with the very best being 74.55x and the bottom being 66.15x. On the higher worth band, the itemizing (post-issue) market capitalisation of Manipal can be roughly ₹77,606 crore, and the corporate is demanding a P/E of ~76x on Fiscal 2026 diluted EPS of ₹7.77 (Pre-issue). When in comparison with its friends, the problem seems totally valued, sitting at a premium to the peer common. This premium displays the corporate’s scale management and industry-leading development, however is ready in opposition to a modest Fiscal 2026 RoNW of 10.57% and a yr through which revenue after tax declined; the case for the premium subsequently rests on post-issue deleveraging and sustained high-acuity development relatively than on present returns. Based mostly on the above views, we assign a Subscribe ranking to the IPO.

Disclaimer: Investments within the securities market are topic to market dangers, learn all associated paperwork fastidiously earlier than investing. Securities quoted listed below are exemplary, not recommendatory. Please seek the advice of your monetary advisor earlier than investing. Please word that we don’t assure any assured returns for the securities quoted right here.

Analysis disclaimer: Funding within the securities market is topic to market dangers. Learn all of the associated paperwork fastidiously earlier than investing. Registration granted by SEBI, and certification from NISM under no circumstances assure the efficiency of the middleman or present any assurance of returns to buyers.

For extra particulars, please learn the disclaimer.

Publish Views:
1,630